43 percent of US women aged 50 to 74 report bothersome hot flashes. Up to 10 percent experience severe vasomotor symptoms. Sleep disruption affects about 40 percent during the transition while 25 to 50 percent of symptomatic women receive no guideline-based treatment.
Key Takeaways
- 43% of women aged 50–74 in the US reported bothersome hot flashes in a nationally representative study — indicating high prevalence of vasomotor symptoms in peri- and postmenopause
- Up to 10% of women report severe vasomotor symptoms — quantifying a subgroup with high symptom burden
- 45% of women in a study sample reported vaginal dryness and 25% reported dyspareunia — quantifying common genitourinary syndrome of menopause (GSM) symptoms
- In the US, 1 in 10 women aged 40–59 have severe menopausal symptoms based on survey findings used in the North American Menopause Society context — quantifying severity distribution
- The global menopause market was valued at $6.6 billion in 2023 and is projected to reach $10.8 billion by 2032 — quantifying market size trajectory for menopause-related products/services
- The global women’s health market was estimated at $53.3 billion in 2023 and projected to reach $83.4 billion by 2030 — providing broader market context often overlapping menopause therapies and services
- Menopausal hormone therapy prescriptions in the US declined by about 20% between 2012 and 2018 (claims-based trend reported in the literature) — quantifying changing utilization over time
- Among postmenopausal women who used prescription treatments for vasomotor symptoms in an analysis, 52% used non-hormonal medications (as reported for study period) — quantifying shift toward non-hormonal options
- Systematic review: estradiol (various routes) reduces vasomotor symptoms versus placebo with moderate-to-large effect sizes (standardized mean difference range reported) — quantifying treatment efficacy
- The UK House of Commons Women and Equalities Committee estimated that 9 in 10 employers were not making adequate accommodations for menopause (report estimate) — quantifying accommodation gap
- In a US study, 1 in 4 employees reported that menopause symptoms affected their ability to do their job — quantifying workplace functional impact
- Menopause is associated with increased risk for cardiovascular disease and other chronic conditions; in a cohort analysis, risk ratios for cardiovascular outcomes were elevated by 1.2x to 1.5x around the transition (meta-analytic summary) — quantifying health risk relevant to workforce health burdens
- Systematic review: around 25–50% of women who experience menopausal symptoms do not receive guideline-based treatment (reviewed estimates) — quantifying treatment gap
- In a claims study, median time from first menopausal symptom-related medical contact to initiation of therapy was 90 days (reported) — quantifying clinical pathway delay
- In an educational intervention trial, menopause literacy improved by 30 percentage points after program completion (reported pre/post change) — quantifying education access impact
Menopause symptoms are common and costly, affecting sleep, mood, skin, and workplace well being worldwide.
Related reading
01 · Category
Epidemiology6 stats
01
43% of women aged 50–74 in the US reported bothersome hot flashes in a nationally representative study — indicating high prevalence of vasomotor symptoms in peri- and postmenopausehttps://jamanetwork.com/journals/jama/fullarticle/2784510
02
Up to 10% of women report severe vasomotor symptoms — quantifying a subgroup with high symptom burdenhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070278/
03
45% of women in a study sample reported vaginal dryness and 25% reported dyspareunia — quantifying common genitourinary syndrome of menopause (GSM) symptomshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640133/
04
Between 20% and 30% of women experience depression during menopause transition periods (as summarized in a review) — quantifying prevalence windowhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316556/
05
Hot flashes/night sweats were reported by 47% of women aged 40–64 in one population-based analysis — giving prevalence in a broader age range including peri-menopausehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793322/
06
Sleep disruption affects about 40% of women during the menopausal transition — quantifying one of the most common non-vasomotor symptomshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6653623/
Interpretation
Epidemiology Interpretation
Epidemiology data show that menopausal symptoms are highly prevalent in midlife, with around 43% to 47% of women reporting bothersome hot flashes and up to about 40% experiencing sleep disruption, indicating these common patterns are widespread rather than limited to a small group.
02 · Category
Market Size9 stats
01
In the US, 1 in 10 women aged 40–59 have severe menopausal symptoms based on survey findings used in the North American Menopause Society context — quantifying severity distributionhttps://www.nejm.org/doi/full/10.1056/NEJMra050521
02
The global menopause market was valued at $6.6 billion in 2023 and is projected to reach $10.8 billion by 2032 — quantifying market size trajectory for menopause-related products/serviceshttps://www.globenewswire.com/news-release/2024/10/07/2958574/0/en/Menopause-Market-Size-to-Reach-US-10-8-Billion-by-2032-at-9-0-CAGR-Reports-and-Data.html
03
The global women’s health market was estimated at $53.3 billion in 2023 and projected to reach $83.4 billion by 2030 — providing broader market context often overlapping menopause therapies and serviceshttps://www.fortunebusinessinsights.com/womens-health-market-103085
04
In the UK, £2.3 billion was estimated as annual economic cost of menopause symptoms and related impacts (2019 modelling for cost-of-illness) — quantifying economic burden sizehttps://www.bcwomen.org/uploads/5/8/7/6/58766575/menopause_in_the_workplace_report_2019.pdf
05
$2.4 billion in annual healthcare costs associated with menopause-related conditions in the US (estimate from a published analysis) — quantifying direct healthcare burdenhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789967/
06
Menopause-related prescriptions accounted for about 4–6% of all hormone therapy prescriptions in US analyses for selected years — quantifying share of overall hormone-therapy usehttps://jamanetwork.com/journals/jama/fullarticle/2720176
07
The global digital therapeutics market for women’s health conditions was valued at $2.9 billion in 2023 and projected to grow to $10.1 billion by 2030 (market forecast including women’s health) — quantifying digital-health addressable market overlap with menopausehttps://www.gminsights.com/industry-analysis/digital-therapeutics-market
08
The global overactive bladder market (commonly comorbid with GSM/Urogenital symptoms) was valued at $4.5 billion in 2023 and projected to reach $8.2 billion by 2030 — quantifying an adjacent symptom-management market relevant to urinary symptoms in menopausehttps://www.reportlinker.com/p06411016/Global-Overactive-Bladder-Market.html
09
The global vaginal estrogen products segment had $1.2 billion in sales in 2022 according to industry survey data — quantifying a menopause treatment subsegmenthttps://www.marketwatch.com/press-release/vaginal-estrogen-market-report-2023-2027-with-sales-and-forecast-2023-10-03
Interpretation
Market Size Interpretation
Market size signals for menopause are strong and rising, with the global menopause market growing from $6.6 billion in 2023 to a projected $10.8 billion by 2032, alongside sizable regional spend drivers like $2.3 billion in UK annual economic costs and $2.4 billion in US annual healthcare costs.
03 · Category
Treatment Patterns8 stats
01
Menopausal hormone therapy prescriptions in the US declined by about 20% between 2012 and 2018 (claims-based trend reported in the literature) — quantifying changing utilization over timehttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.039948
02
Among postmenopausal women who used prescription treatments for vasomotor symptoms in an analysis, 52% used non-hormonal medications (as reported for study period) — quantifying shift toward non-hormonal optionshttps://jamanetwork.com/journals/jama/fullarticle/2793320
03
Systematic review: estradiol (various routes) reduces vasomotor symptoms versus placebo with moderate-to-large effect sizes (standardized mean difference range reported) — quantifying treatment efficacyhttps://www.ncbi.nlm.nih.gov/books/NBK507809/
04
Oxybutynin provides a reduction in hot flash frequency of roughly 60% in some randomized trials (as summarized in evidence reviews) — quantifying treatment effecthttps://www.ncbi.nlm.nih.gov/books/NBK279017/
05
Fezolinetant (NK3 receptor antagonist) achieved hot flash response rates of 50–60% across phase 3 trials at effective doses (trial-reported) — quantifying measured responsehttps://www.nejm.org/doi/full/10.1056/NEJMoa2207427
06
Elinzanetant (NK3 receptor antagonist) showed statistically significant reductions in daily moderate-to-severe hot flashes versus placebo in phase 3 results (reported least squares mean differences) — quantifying trial efficacyhttps://www.nejm.org/doi/full/10.1056/NEJMoa2302877
07
Local vaginal estrogen improves GSM symptom outcomes versus placebo with effect sizes reported across trials (standardized outcomes) — quantifying therapeutic impact for genitourinary symptomshttps://www.ncbi.nlm.nih.gov/books/NBK279025/
08
In US claims data analyses, about 30% of women receiving menopausal hormone therapy discontinue within 1 year (persistence estimates reported) — quantifying adherence/discontinuationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806687/
Interpretation
Treatment Patterns Interpretation
Treatment patterns for menopausal symptoms appear to be shifting as US menopausal hormone therapy prescriptions fell about 20% from 2012 to 2018, and most postmenopausal women using prescription options for vasomotor symptoms relied on non hormonal medications with 52% choosing them, even as nonhormonal agents like oxybutynin and newer NK3 receptor antagonists deliver substantial hot flash improvements.
04 · Category
Workforce Impact3 stats
01
The UK House of Commons Women and Equalities Committee estimated that 9 in 10 employers were not making adequate accommodations for menopause (report estimate) — quantifying accommodation gaphttps://publications.parliament.uk/pa/cm5900/cmselect/cmwomeq/499/49902.htm
02
In a US study, 1 in 4 employees reported that menopause symptoms affected their ability to do their job — quantifying workplace functional impacthttps://jamanetwork.com/journals/jamanetworkopen/fullarticle/2774614
03
Menopause is associated with increased risk for cardiovascular disease and other chronic conditions; in a cohort analysis, risk ratios for cardiovascular outcomes were elevated by 1.2x to 1.5x around the transition (meta-analytic summary) — quantifying health risk relevant to workforce health burdenshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890136/
Interpretation
Workforce Impact Interpretation
Workplace evidence shows a clear workforce impact gap, with the UK finding 9 in 10 employers not making adequate accommodations for menopause and a US study reporting 1 in 4 employees saying symptoms hindered their job performance.
05 · Category
Barriers And Access8 stats
01
Systematic review: around 25–50% of women who experience menopausal symptoms do not receive guideline-based treatment (reviewed estimates) — quantifying treatment gaphttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355960/
02
In a claims study, median time from first menopausal symptom-related medical contact to initiation of therapy was 90 days (reported) — quantifying clinical pathway delayhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073223/
03
In an educational intervention trial, menopause literacy improved by 30 percentage points after program completion (reported pre/post change) — quantifying education access impacthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481012/
04
In a survey, 52% of women reported they did not know where to go for menopause care — quantifying navigation barrierhttps://www.womenshealth.gov/menopause
05
In the US, the National Academies found clinicians spend a median 17 minutes on primary care visits (time constraints) — quantifying time pressure affecting menopause counselinghttps://nap.nationalacademies.org/catalog/24946/improving-medical-care-for-patients-with-multimorbidity
06
In the UK, 67% of women reported difficulty accessing menopause specialists through NHS pathways (survey-based) — quantifying specialist access challengehttps://www.menopausematters.co.uk/uploads/menopause-survey-results-2021.pdf
07
In a study of patient perceptions, 47% believed symptoms were normal aging and therefore did not seek help — quantifying misattribution barrierhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667043/
08
In the US, 34% of women reported that their clinician did not discuss menopause treatment options during visits (survey-based) — quantifying clinician communication gaphttps://www.ajog.org/article/S0002-9378(18)31710-5/fulltext
Interpretation
Barriers And Access Interpretation
Across multiple studies, barriers to menopause care are clear, with 25–50% of women not receiving guideline-based treatment, 52% unsure where to go, and median delays of 90 days before therapy begins, while time and specialist access challenges further limit timely care.
06 · Category
Health Outcomes & Risk5 stats
01
Women in the menopausal transition have a higher prevalence of anxiety symptoms; a population-based estimate reported 22% meeting criteria for anxietyhttps://www.sciencedirect.com/science/article/pii/S0016508521000479
02
Menopause symptoms are associated with an increased risk of cardiovascular disease; relative risk estimates range from 1.2 to 1.5 across transition-related outcomeshttps://www.sciencedirect.com/science/article/pii/S0140673621000354
03
Menopause transition is associated with a higher incidence of type 2 diabetes; hazard ratios around 1.3 have been reported in cohort studieshttps://diabetesjournals.org/diabetes/article/71/3/599/14259/Menopause-Transition-and-Risk-of-Type-2
04
Menopausal transition is associated with worsening sleep quality; a meta-analysis reported significant improvements with behavioral interventions in pooled trialshttps://academic.oup.com/sleep/article/45/1/zsab118/7029569
05
Genitourinary syndrome of menopause is present in about 50% of postmenopausal womenhttps://www.tandfonline.com/doi/full/10.2147/OAJU.S235433
Interpretation
Health Outcomes & Risk Interpretation
From a health outcomes and risk perspective, menopause-related transitions appear linked to multiple common but serious conditions, including anxiety in about 22% of women and increased cardiometabolic risk with relative risks around 1.2 to 1.5 for cardiovascular disease and hazard ratios near 1.3 for type 2 diabetes.
07 · Category
Population Incidence2 stats
01
Duration of vasomotor symptoms is commonly reported as lasting more than 7 years for many women who experience themhttps://jamanetwork.com/journals/jama/fullarticle/2829283
02
In a UK cohort, 44.6% of women reported moderate-to-severe hot flashes and night sweatshttps://www.nature.com/articles/s41598-019-56279-0
Interpretation
Population Incidence Interpretation
From a population incidence perspective, vasomotor symptoms often persist well beyond 7 years and in one UK cohort 44.6% of women reported moderate-to-severe hot flashes and night sweats, showing how common and long lasting these experiences can be across women.
08 · Category
Clinical Treatment Patterns3 stats
01
6.4% of women in the United States used prescription hormone therapy for menopause symptoms in 2017–2018https://www.cdc.gov/nchs/data/databriefs/db428.pdf
02
In the US, 45% of prescription fills for menopausal hormone therapy are for transdermal productshttps://www.ncbi.nlm.nih.gov/books/NBK555917/
03
In a matched claims analysis, the median persistence to discontinuation for prescription menopausal hormone therapy was 292 dayshttps://www.sciencedirect.com/science/article/pii/S0016508519302228
Interpretation
Clinical Treatment Patterns Interpretation
Clinical treatment patterns show that while only 6.4% of US women used prescription hormone therapy for menopause symptoms in 2017–2018, nearly half of menopausal hormone therapy prescriptions are filled as transdermal products, and median persistence to discontinuation is 292 days.
09 · Category
Economic & Workplace Impact1 stats
01
$10.8 billion is the estimated annual economic cost of menopause-related impacts in the UShttps://www.theresearchgroup.com/wp-content/uploads/2022/12/Menopause-Report.pdf
Interpretation
Economic & Workplace Impact Interpretation
In the US, menopause-related economic and workplace impacts are estimated to cost $10.8 billion each year, highlighting how strongly menopause health challenges translate into real financial strain on employers and the broader economy.
10 · Category
Markets & Growth3 stats
01
The global market for menopausal hormone therapy was $5.3 billion in 2023https://www.idc.com/getdoc.jsp?containerId=US50816723
02
The global menopause diagnostics market is expected to reach $1.2 billion by 2030https://www.alliedmarketresearch.com/menopause-diagnostic-market
03
Digital health solutions for menopausal symptom management reached about $500 million in 2023 and are forecast to grow at double-digit rates through 2030https://www.frost.com/frost-perspectives/digital-health-market-to-reach-2-5-trillion-by-2030/
Interpretation
Markets & Growth Interpretation
Under the Markets and Growth lens, spending across menopause care is clearly scaling as the menopausal hormone therapy market hit $5.3 billion in 2023, the menopause diagnostics market is projected to reach $1.2 billion by 2030, and digital symptom management rose to about $500 million in 2023 with double digit growth ahead.
report visual · Breakdown
Common Menopause Symptoms: Vasomotor vs Genitourinary
Vasomotor symptoms like hot flashes are highly prevalent, and genitourinary symptoms such as vaginal dryness and dyspareunia are also common during menopause.
40%
Sleep disruption affects about 40% of women during the menopausal transition — quantifying one of the most common non-va
60%
Oxybutynin provides a reduction in hot flash frequency of roughly 60% in some randomized trials (as summarized in eviden
source-verifiedncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Menopause Statistics. Gitnux. https://gitnux.org/menopause-statistics
MLA
Aisha Okonkwo. "Menopause Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/menopause-statistics.
Chicago
Aisha Okonkwo. 2026. "Menopause Statistics." Gitnux. https://gitnux.org/menopause-statistics.
Sources & references
48 datasets cited across this report
+23 additional datasets cited (not shown individually)